PPH Legal Blog

Bayer Schering Pharma has reported positive findings during the first round of clinical trials for its oral pulmonary hypertension treatment, Riociguat. The development of this drug is the first in its class of vasodilating agents.
The trials, being successful so far, will now move onto a Phase III study in late 2008 to determine the full […]

[Read more →]

A Texas police chief who was trying to stay trim back in the 1990s has recently learned the true effects of the Metabolife that he took to stay thin. Unfortunately, the Metabolife contained primary pulmonary hypertension causing ephedra.
According to Leo Longoria, the police chief, he began to experience a rapid heart rate and high blood […]

[Read more →]

The United States Food and Drug Administration has been investigating the drug Avandia for some time now. In early 2008, the FDA issued a warning letter to the drug’s manufacturer, GlaxoSmithKline, for postmarketing safety reporting failures.
The large manufacturer claims that any information that was withheld was done so by mistake. GlaxoSmithKline states that the missing […]

[Read more →]

Recent studies have shown that the drug known as Viagra has been successful in the treatment of primary pulmonary hypertension (PPH) in infants. Viagra, best known to treat erectile dysfunction in adult males, has proven to be effective as a pulmonary dilator.
According to doctors, Viagra works to loosen and relax the constricted arteries of a […]

[Read more →]

In early July, GeneraMedix was approved by the FDA for its Epoprostenol for injection 1.5mg drug. GeneraMedix’s Epoprostenol for injection 1.5mg is meant to be a long-term intravenous treatment for primary pulmonary hypertension (PPH).
PHH is caused by the thinning or narrowing of the blood vessels that supply the lungs. If left untreated, an individual’s blood […]

[Read more →]